China News Service, Beijing, December 31st, title: How much is the progress of research and development?

Is the vaccination uncomfortable?

China's official analysis of the new crown vaccine

　　China News Agency reporter Zhu Chenxi Zhang Su

　　The Joint Prevention and Control Mechanism of the State Council of China held a press conference on the 31st to announce the conditional listing of China's first new coronavirus vaccine.

Regarding the current progress of China's five technical routes of vaccine research and development, whether there is any discomfort after vaccination, and the situation of international vaccine cooperation, the reporter sorted out the following issues.

　　Research and development: 5 technical routes and 14 vaccines have entered clinical trials

　　Xu Nanping, Vice Minister of the Ministry of Science and Technology of China, introduced at the press conference that so far, 14 vaccines from 5 technical routes in China have entered clinical trials, of which 3 technical routes and 5 vaccines have entered phase III clinical trials.

　　"In the process of vaccine development and production, we always put the safety and effectiveness of vaccines in the first place." Zeng Yixin, deputy director of the National Health Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said, China Vaccine research and development work has always been in the world's first square.

　　Looking back on the development path of China's new crown vaccine, on April 2 this year, the world's first inactivated new crown vaccine was approved for phase I and II clinical trials; on June 23, the world's first phase III clinical trial was launched; June 24 On December 30, after strict procedures, the emergency use of vaccines was approved in accordance with laws and regulations; since July, a number of vaccines have been overseas for phase III clinical trials; on December 30, the first domestic vaccine was approved for conditional marketing.

　　"In the next step, we will continue to go all out to speed up vaccine research and development, and never relax." Xu Nanping said that first, we must accelerate the advancement of phase III clinical trials and provide more vaccine products with different technical routes.

The second is to pay close attention to global virus mutations and related developments, and scientifically respond to ensure that the use of vaccines is not affected.

The third is to continue to increase basic research on vaccines to provide solid scientific and technological support for epidemic prevention and control.

　　Vaccination: 4.5 million doses have been inoculated with good safety

　　It is understood that China began emergency use of the new crown vaccine in June this year, and by the end of November, it had accumulated more than 1.5 million doses.

On December 15, a large-scale vaccination of key populations was carried out. In the past two months, the cumulative vaccination of key populations nationwide has exceeded 3 million doses.

　　"This 3 million, plus the previous 1.5 million, fully proves that our vaccine is safe." Zeng Yixin said that the incidence of adverse reactions is close to that of routine inactivated vaccines, and there are probably less cases of mild fever. 0.1%, the incidence of relatively serious adverse reactions such as allergic reactions is about two per million.

These conditions have been dealt with in time and have been well treated.

　　Zeng Yixin said that in the next step, with the approval of the vaccine's conditional marketing, according to the improvement of vaccine supply and guarantee capacity, vaccination will gradually expand to high-risk groups, mainly including the elderly and people with underlying diseases.

The third step is to expand to the entire population of vaccination.

　　Regarding the establishment of the immune barrier and the proportion of the population that needs to be vaccinated, Zeng Yixin believes that a coverage rate of 60% or even 70% can be achieved to establish protection for the whole people.

　　"A major premise is that it must be provided free of charge for all people." Zeng Yixin said, advocating people to actively participate in vaccination on the premise of informed consent and elimination of contraindications, to achieve "should be connected", and gradually build an immune barrier for the entire population .

　　International cooperation: fulfilling promises and making vaccines a global public product

　　China has always been open to international cooperation in vaccines. On October 8, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the “New Coronary Pneumonia Vaccine Implementation Plan”. This is China’s adherence to the concept of a community of human health and promoting vaccines to become a global public. Important product initiatives.

　　The head of the International Department of the Ministry of Foreign Affairs, Shen Bo, said at the press conference that the Chinese government has been actively supporting the "New Coronary Pneumonia Vaccine Implementation Plan" and expects that China's vaccine will be selected into the "Implementation Plan" vaccine library as soon as possible and will be pre-certified by the World Health Organization as soon as possible.

　　In fact, many Chinese vaccine companies have already expressed their positive willingness to join the "Implementation Plan" sponsors, and are also negotiating vaccine supply plans with different countries.

Shen Bo said that the Chinese government has been actively encouraging and supporting Chinese vaccine research and development companies to participate in the "implementation plan", and cooperate with relevant sponsors to provide vaccines to developing countries. After China's new crown vaccine is completed and put into use, it will firmly fulfill its commitments and use vaccines as a vaccine. Global public products are supplied to the world at fair and reasonable prices.

　　Wu Yonglin, President of Sinopharm China Biotechnology Co., Ltd., introduced at the press conference that Sinopharm’s China Biotech Covid-19 vaccine has conducted large-scale phase III clinical trials in many countries such as the UAE and Bahrain. The number of people inoculated has exceeded 60,000. The population sample size covers 125 nationalities.

　　"In the process of advancing vaccine research and development, Chinese vaccine companies and research and development units have only one opponent, which is the virus." Zheng Zhongwei, head of the vaccine research and development working group of the Joint Prevention and Control Mechanism Research Group of the State Council, said that throughout the research and development process, we fully respect science. Laws, scientific principles.

Because only a vaccine can truly become a public product if its safety and effectiveness are guaranteed, and its accessibility and affordability are relatively good.

(Finish)